The BCR-ABL1 oncoprotein transforms pluripotent HSCs and initiates chronic myeloid
leukemia (CML). Patients with early phase (also known as chronic phase [CP]) disease …

Chronic myelogenous leukemia (CML) evolves from a chronic phase characterized by the
Philadelphia chromosome as the sole genetic abnormality into blast crisis, which is often …

The BCR/ABL oncogenic tyrosine kinase activates phosphatidylinositol 3‐kinase (PI‐3k) by
a mechanism that requires binding of BCR/ABL to p85, the regulatory subunit of PI‐3k, and …

MicroRNA miR-125b has been implicated in several kinds of leukemia. The chromosomal
translocation t (2; 11)(p21; q23) found in patients with myelodysplasia and acute myeloid …

Chronic myeloid leukemia (CML) is characterized by the presence of the BCR-ABL1 fusion
gene, which encodes a constitutive active tyrosine kinase considered to be the pathogenic …

Bcr–Abl is a chimeric oncoprotein that is strongly implicated in acute lymphoblastic (ALL)
and chronic myelogenous leukemias (CML). This deregulated tyrosine kinase selectively …

The NPM/ALK fusion gene, formed by the t (2; 5) translocation in a subset of anaplastic large
cell lymphomas, encodes a M r 75,000 hybrid protein that contains the NH2-terminal portion …

Over the last decade, a growing number of tumor suppressor genes have been discovered
to play a role in tumorigenesis. Mutations of p53 have been found in hematological …

Signal transducer and activator of transcription (STAT) 5 is constitutively activated in
BCR/ABL-expressing cells, but the mechanisms and functional consequences of such …

In a BCR/ABL-expressing myeloid precursor cell line, p53 levels were markedly
downmodulated. Expression of MDM2, the negative regulator of p53, was upregulated in a …